Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451736 · ClinicalTrials.gov registry record · Phase 4
Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
A Phase 4 study of Schizophrenia (Recent-onset), sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 146
- Enrollment target
- 1
- Study location
NCT01451736: Completed Phase 4 study of Schizophrenia (Recent-onset), sponsored by University of California, Los Angeles.
NCT01451736 is a Phase 4 study of Schizophrenia (Recent-onset) that has completed, run by University of California, Los Angeles. The registered enrollment target is 146 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01451736, a Phase 4 study of Schizophrenia (Recent-onset), has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 146 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.
Primary Outcome
Exacerbation or relapse of psychotic symptoms, as measured by the Brief Psychiatric Rating Scale (BPRS)
Conditions Studied
Interventions
- DRUG risperidone
- DRUG paliperidone palmitate
Study Locations (1)
California
- UCLA Semel Institute for Neuroscience and Human Behavior - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2011-10 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
What the finished NCT01451736 record still lists
NCT01451736 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Schizophrenia (Recent-onset) appearing as the primary indexed condition, and to 2 interventions - of which risperidone is the first listed.
NCT01451736 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01451736 about?
NCT01451736 is a clinical study titled "Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia". This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.
What is the current status of trial NCT01451736?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 146 participants. The study started on 2011-10. Estimated completion is 2021-12-31.
What conditions does trial NCT01451736 study?
This clinical trial studies the following conditions: Schizophrenia (Recent-onset).
What interventions are being tested in trial NCT01451736?
The interventions under investigation include: risperidone (DRUG), paliperidone palmitate (DRUG).
Who is sponsoring clinical trial NCT01451736?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01451736 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01451736's enrollment target sits among peer trials
146 571st of 2000 higher than 1,429 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia